. 2018 Oct 16;13(10):e0205864. doi: 10.1371/journal.pone.0205864

Table 1. Univariate and multivariate analysis of clinico-pathological factors affecting 5-year overall survival in primary BTC.

(A) Extrahepatic cholangiocarcinoma
Clinico-pathological parameter		Number	Univariate analysis		Multivariate analysis
Clinico-pathological parameter		Number	5yOS (%)	p value	HR^*	95%CI^*	p value
Age	≥65 / <65	46 / 35	41 / 55	0.31
Gender	Male / Female	59 / 22	42 / 64	0.16
Preoperative jaundice	absence / presence	40 / 41	47 / 47	0.81
Biliary drainage	absence / presence	13 / 68	64 / 44	0.19
Preoperative serum CA19-9	≥37 / <37	52 / 29	35 / 74	0.0084	2.3	1.0–5.9	0.047
Preoperative serum CEA	≥5 / <5	4 / 77	0 / 49	0.12
Tumor location	Bp / Bd	18 / 63	43 / 48	0.79
Lymphatic permeation	absence / presence	18 / 63	76 / 40	0.0047	1.6	0.52–7.4	0.42
Vascular permeation	absence / presence	25 / 56	59 / 43	0.22
Portal venous invasion	absence / presence	77 / 4	49 / 25	0.0003
Arterial system invasion	absence / presence	78 / 3	48 / 33	0.49
Perineural invasion	absence / presence	22 / 59	80 / 36	0.0021	3.1	1.2–11	0.018
Macroscopic growth pattern	invasive / others	71 / 10	45 / 68	0.25
Histology	tub1, pap / others	49 / 32	53 / 39	0.23
Resection status	R0 / R1, 2	43 / 38	57 / 36	0.04	1.4	0.71–2.7	0.34
CDO1 TaqMeth value	≥28.9 / <28.9	22 / 59	22 / 56	0.0018	2.4	1.2–4.7	0.016
the sixth TNM classification
pT	Tis,T1 / T2 / T3 / T4	10 / 12 / 31 / 28	100 / 56 / 40 / 34	0.01
pN	absence / presence	43 / 38	66 / 27	0.0002
pStage				0.016			0.079
	0, IA, IB	15	76		Reference
	IIA	17	61		1.0	0.25–5.1
	IIB	21	33		2.0	0.58–9.7
	III	28	34		3.0	0.90–14
Operative procedure	PD / Liver resection / others	64 / 14 / 3	49 / 42 / 33	0.64
Postoperative jaundice	absence / presence	70 /11	47 / 55	0.75
Postoperative serum CA19-9	≥37 / <37	19 / 62	31 / 52	0.077
Postoperative serum CEA	≥5 / <5	2 / 79	100 / 46	0.21
Postoperative chemotherapy	absence / presence	20 / 61	62 / 43	0.34
(B) Ampullary carcinoma
Clinico-pathological parameter		Number	Univariate analysis		Multivariate analysis
Clinico-pathological parameter		Number	5yOS (%)	p value	HR^*	95%CI^*	p value
Age	≥65 / <65	16 / 11	65 / 82	0.57
Gender	Male / Female	16 / 11	70 / 81	0.66
Preoperative jaundice	absence / presence	16 / 11	88 / 61	0.24
Biliary drainage	absence / presence	4 / 23	100 / 70	0.31
Preoperative serum CA19-9	≥37 / <37	11 / 16	57 / 88	0.19
Preoperative serum CEA	≥5 / <5	1 / 26	0 / 76	0.0068		1.5	0.06–20	0.76
Lymphatic permeation	absence / presence	11 / 16	100 / 59	0.036	1.6E+08	0.04-	0.52
Vascular permeation	absence / presence	10 / 17	100 / 60	0.047		1.2E+08	0.03-	0.58
Portal venous invasion	absence / presence	27 / 0	74 / -
Arterial system invasion	absence / presence	27 / 0	74 / -
Perineural invasion	absence / presence	21 / 6	86 / 25	0.0008	1.0	0.04–15	0.99
Macroscopic growth pattern	invasive / others	11 / 16	32 / 94	0.014		4.0	0.28–97	0.29
Histology	tub1, pap / others	21 / 6	75 / 67	0.49
Resection status	R0 / R1, 2	24 / 3	83 / 0	<0.0001	4.3	0.37–101	0.24
CDO1 TaqMeth value	≥28.9 / <28.9	9 / 18	66 / 78	0.89
the sixth TNM classification
pT	Tis,T1 / T2 / T3 / T4	9 / 4 / 14 / 0	100 / 100 / 54 / -	0.052
pN	absence / presence	11 / 16	91 / 65	0.25
pStage	0, IA, IB / IIA / IIB / III	8 / 3 / 16 / 0	100 / 67 / 65 / -	0.26
Postoperative jaundice	absence / presence	27 / 0	74 / -
Postoperative serum CA19-9	≥37 / <37	5 / 22	50 / 82	0.45
Postoperative serum CEA	≥5 / <5	1 / 26	100 / 73	0.68
Postoperative chemotherapy	absence / presence	10 / 17	90 / 66	0.29

*HR: hazard ratio, CI: confidence interval